Guardant Health, Inc. (NASDAQ:GH) Director Meghan V. Joyce Sells 2,896 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. This trade represents a 27.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Guardant Health Stock Performance

Guardant Health stock traded down $0.80 on Friday, reaching $29.41. The company’s stock had a trading volume of 293,926 shares, compared to its average volume of 2,063,913. The business’s fifty day moving average price is $23.57 and its 200 day moving average price is $26.33. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $37.04.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. During the same quarter last year, the company earned ($0.73) EPS. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. As a group, equities research analysts forecast that Guardant Health, Inc. will post -3.38 EPS for the current year.

Institutional Trading of Guardant Health

Several hedge funds have recently modified their holdings of GH. Allspring Global Investments Holdings LLC bought a new position in Guardant Health in the first quarter valued at about $273,000. Swiss National Bank grew its position in shares of Guardant Health by 3.3% during the 1st quarter. Swiss National Bank now owns 227,700 shares of the company’s stock worth $4,697,000 after buying an additional 7,300 shares during the period. ProShare Advisors LLC grew its position in shares of Guardant Health by 9.4% during the 1st quarter. ProShare Advisors LLC now owns 29,317 shares of the company’s stock worth $605,000 after buying an additional 2,518 shares during the period. State Board of Administration of Florida Retirement System raised its stake in shares of Guardant Health by 254.0% during the first quarter. State Board of Administration of Florida Retirement System now owns 114,125 shares of the company’s stock worth $2,354,000 after buying an additional 81,887 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp acquired a new position in Guardant Health in the first quarter valued at approximately $8,300,000. 92.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on GH shares. JPMorgan Chase & Co. upped their target price on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. TD Cowen lifted their target price on shares of Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Citigroup upped their target price on shares of Guardant Health from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. The Goldman Sachs Group lifted their price objective on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Bank of America upped their price objective on Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, July 18th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.60.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.